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Abstract
Introduction: Previous studies had enlisted renal medullary carcinoma (RMC) as the seventh nephropathy in sickle cell disease 
(SCD). Clinical experience has contradicted this claim and this study is targeted at refuting or supporting this assumption.
Objective: To estimate the prevalence of  RMC and describe other renal complications in SCD.
Materials and methods: 14 physicians (haematologists and urologists) in 11 tertiary institutions across the country were col-
lated from patients’ case notes and hospital SCD registers.
Results: Of  the 3,596 registered sickle patients, 2 (0.056%) had been diagnosed with RMC over a ten year period, thereby giving 
an estimated prevalence rate of  5.6 per 100,000. The most common renal complication reported by the attending physicians was 
chronic kidney disease (CKD). The frequency of  routine renal screening for SCD patients varied widely between centres – most 
were done at diagnosis, annually or bi-annually.
Conclusion: The ten year prevalence of  RMC in Nigerian SCD patients was determined to be 5.6 (estimated incidence of  0.56). 
RMC is not more common in SCD patients and therefore cannot be regarded as a “Seventh Sickle nephropathy”. Most of  the 
managing physicians reported that the commonest nephropathy observed in their SCD patients was chronic kidney disease.
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Sickle cell disease (SCD) is caused by an inherited point 
mutation causing replacement of  the hydrophilic polar 
amino acid glutamate by a less polar hydrophobic amino 
acid, valine at the 6th position of  the beta globin chain. 
The prevalence of  carriers state - sickle cell trait (haemo-
globin AS - HbAS) ranges between 10 and 40% across 
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equatorial Africa, decreases to 1-2% in North Africa, and 
to less than 1% in parts of  Africa south of  river Zambesi 
1. The incidence of  SCD at birth is determined by the 
prevalence of  carriers in the population. SCD has pro-
found public health implications in Africa as it contrib-
utes about 5% to under-five mortality, with up to 16% oc-
curring in West Africa. Globally, about 300,000 children 
are born every year with SCD2 and Nigeria accounts for 
one-third of  this population of  people living with sickle 
cell1.
In 1974, Berman described 6 nephropathies that occur 
in people who have either SCD or sickle cell trait which 
were attributed to vascular stagnation, reduced oxygen 
pressure and renal medullary hypertonicity3.The 6 ne-
phropathies were gross haematuria, papillary necrosis, 
nephrotic syndrome, renal infarction, hyposthenuria and 
pyelonephritis. Previous reports had described RMC as 
a rare tumor of  kidney that notably occurred in young 
African American patients with SCD4 or sickle cell trait, 
which they proposed to call the “seventh sickle cell nephropa-
thy”5,6. Renal medullary carcinoma as a tumor is rare, very 
aggressive (with death often occurring within one year of  
diagnosis) and resistant to immunotherapy and chemo-
therapy. The age incidence of  renal medullary carcinoma 
ranges from 11 to 39 years, with male preponderance 
(3:1) in patients under the age of  25 years5. The relative-
ly young age of  patients with this carcinoma prompted 
the search for genetic factors likely to be involved in its 
pathogenesis. Cytogenetics revealed monosomy 11 in 4 
out of  6 successfully karyotyped tumors7. Studies that 
are more recent have shown the loss or alteration of  
SMARCB1/INI1 gene with increased cyclinD1 expres-
sion as a possible molecular pathogenetic causative path-
way8. However, all the patients had sickle cell trait and, 
coincidentally, the beta globin gene locus is in the short 
arm of  chromosome 11. A possible relationship might be 
that chromosome 11 is involved in the development of  
renal medullary carcinoma.
This kidney tumour may be diagnosed by ultrasonogra-
phy, excretory urography or computed tomography5,9.It 
usually involves the central portion of  kidney and ultraso-
nography shows a centrally located solid space-occupying 
lesion of  kidney with heterogeneous echogenicity. It may 
not be well visualized on excretory urography which oc-
casionally shows evidence of  a kidney mass and distor-
tion of  the adjacent calyx. Computed tomography (CT) 
reveals infiltrative and indistinct masses that usually arise 
in the central region of  the kidney, with invasion of  the 
renal sinus fat. CT contrast enhancement shows the le-
sion in all patients, and retroperitoneal lymphadenopa-
thy9. Filling defects in the pelvi-calyceal system may be 
seen on a retrograde pyelography. Ancillary investiga-
tions include ureteroscopy (may reveal a sessile mass le-
sion in the pelvi-calyceal system), angiography (may show 
hypovascular tumour) and cytology of  the urine which 
may detect malignant cells. Nephrectomy for non-me-
tastasized tumours, with removal of  the retroperitoneal 
nodes, is usually the treatment of  choice. Removal of  the 
retroperitoneal lymph nodes is suggested in some cases 
but is not standard in renal cell carcinoma, however it is 
recommended in aggressive tumors such as renal medul-
lary carcinoma. It has not shown to improve survival but 
is helpful for staging10. However, due to the high prolif-
eration rate of  this carcinoma and its tendency to metas-
tasize early, most patients present after the tumour had 
spread; and are treated with chemotherapy11.
Renal medullary carcinoma has long been proposed to be 
one of  the complications of  SCD. Nigeria with a large 
population of  patients living with SCD (1-2 million) is 
a naturally vantage location to evaluate the postulated 
association between this haemoglobinopathy and renal 
medullary carcinoma. The aim of  this study was to deter-
mine the prevalence of  renal cell carcinoma among SCD 
patients in Nigeria, as well as describe the renal complica-
tions found in this patient population.
 
Materials and methods
The study was a hospital-based retrospective descriptive 
analysis obtained from hospital records across Nigerian. 
The survey was done using a 7-item pre-validated (pre-
validation was done with five Physicians who filled the 
draft questionnaire and were not included in the study) 
questionnaire was sent to 22 Physicians (Haematologists 
and Urologists) in 17 tertiary health institutions across 
the different geo-political zones in Nigeria.  The selection 
of  the centers, was non-randomized and questionnaires 
were sent to all centers which the authors had correspon-
dence with. Information included; speciality, number of  
registered patients, data duration, number of  patients 
diagnosed with RMC, frequency and modalities of  renal 
screening in SCD patients as well as the most common 
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renal complication of  SCD recorded in the center. Other 
information obtained included the types of  nephropathy 
encountered in SCD patients seen across the country, and 
the tests for detecting sickle nephropathy recommended 
by the physicians.
Data on a total of  3,596 SCD patients receiving care in 
11 tertiary healthcare institutions across Nigeria who had 
responded, was collected. These tertiary health institu-
tions are located in different geographical expanse of  
the country and receive patients across various states and 
counties, a population ranging from 1-3 million persons. 
The various durations over which the data was captured 
in the participating centers were also obtained and the 
median duration was estimated. The data was used to ob-
tain rates and descriptive data are presented in tables. The 
prevalence of  renal medullary carcinoma was determined 
using IBM SPSS Statistics for windows version 19.0 pack-
age (IBM Corporation, Armonk, NY, USA). Ethical ap-
proval was obtained from the health research and ethics 
committee of  the participating centers.
Results
The respondents to this survey involved included 14 
(64%) physicians in 11(65%) tertiary heath institutions 
across the various geographical populations across the 
country. The 14 physicians who provided data from their 
centers included 11 (78.6%) haematologists, 1(7.1%) 
urologist and 2 (14.3%) pediatricians. Duration over 
which the data was collected varied from 6 to 16 years in 
the different centers, with a median duration of  10 years 
and mean of  10.1 years. Renal medullary carcinoma was 
reported in 2 out of  the 3,596 patients, making the 10 
year prevalence rate 0.056%. Both cases were from the 
same center (Aminu Kano Teaching Hospital Kano), 
which also had the largest pool of  SCD patients – 1,800 
registered patients. One of  the patients was a 32 year old 
house wife who had completed secondary education, and 
her husband was a junior cadre government employee, 
while the other was 28 year old single male patient. Both 
patients were homozygous S and diagnosis was based on 
CT as well as renal biopsy histology. The average num-
ber of  SCD patients registered in each of  the 14 tertiary 
hospital units under study, ranged from 20 – 1500, with 
a median of  128 patients. The number of  SCD patients 
registered in each center is shown in table 1.
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Table 1. Patient distribution and duration of data collection among the participating centers. 
 
Institution   Numbers of registered 
patients (n=3,596) 
Duration of data 
collected (years) 
Aminu Kano Teaching Hospital, 
Kano (Adult clinic) 
  1500 (41.7%) 7 (5.3%) 
University of Nigeria Teaching 
Hospital, Enugu (Paediatrics clinic) 
  350 (9.7%) 10 (7.7%) 
Aminu Kano Teaching Hospital, 
Kano (Urology Clinic) 
  300(8.4%) 10 (7.7%) 
Federal Medical Center, Birinin-
Kebbi, Kebbi State (Adult clinic) 
  300 (8.4%) 6 (4.6%) 
University College Hospital, Ibadan 
(Adult clinic) 
  300 (8.4%) 6 (4.6%) 
University of Calabar Teaching 
Hospital (Adult clinic) 
  215 (5.9%) 10 (7.7%) 
Ahmadu Bello University Teaching 
Hospital, Zaria, Kaduna State(Adult 
clinic) 
  160 (4.5%) 10 (7.7%) 
University of Nigeria Teaching 
Hospital, Enugu(Adult clinic) 
  156 (4.3%) 16 (12.4%) 
NnamdiAzikiwe University Teaching 
Hospital Nnewi (Adult clinic) 
  100 (2.8%) 10 (7.7%) 
Benue State University Teaching, 
Makurdi (Adult clinic) 
  58 (1.7%) 14 (10.8%) 
University of Benin Teaching 
Hospital, Edo State (Adult clinic) 
  56 (1.6%) 10 (7.7%) 
NnamdiAzikiwe University Teaching 
Hospital Nnewi (Paediatrics clinic) 
  55 (1.5%) 7 (5.3%) 
Federal Medical Center, Owerri, 
Imo State (Adult clinic) 
  26 (0.7%) 8 (6.2%) 
University of Port Harcourt 
Teaching Hospital (Adult clinic) 
  20 (0.4%) 6 (4.6%) 
        
Total N(100%) 3596 (100%) 130 (100%) 
  Mean 257   
  Median 128   
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All the respondents included urinalysis as one of  the rou-
tine tests used in screening for sickle nephropathy, 12/14 
(85.7 %) routinely requested renal function test, and 8/14 
(57.1%) did routine abdominal ultrasonography for renal 
evaluation. None of  the centers under study used com-
puterized tomography scan (CT scan) for screening or 
investigating renal disease routinely. The frequency of  
renal screening and evaluation varied widely, from once 
(at diagnosis) to quarterly (once every 3 months). In 3 of  
the centers screening was done at diagnosis only, screen-
ing was done annually in 3 centers and 6-monthly inter-
vals in 4. This is shown in table 2.The commonest renal 
complications of  sickle cell disease observed are shown 
in table 2, the commonest nephropathy observed by the 
physicians in the participating centers was chronic kid-
ney disease (42.9% or 6/14) and proteinuria in 28.6% 
(4/14). Chronic kidney disease is defined as a diminished 
renal function with a reduction in glomerular filtration 
rate with or without kidney damage, while proteinuria re-
fers to excessive protein excretion in urine above normal 
for age and sex. Other less frequent complications were 
papillary necrosis, nephrotic syndrome, renal stones and 
recurrent urinary tract infection.
Table 2. Frequency of renal screening and renal complications observed in sickle cell disease. 
 
Variable   Frequency (n=15) Percentage 
Routine renal screening       
  At diagnosis 4 26.7 
  Seldom 2 13.3 
  3 monthly 2 13.3 
  6 monthly 4 26.7 
  Annually 3 20.0 
Most common renal 
complication 
  Frequency (n=14)   
  CKD 6 42.9 
  Proteinuria 4 28.6 
  Nephrotic syndrome 2 14.3 
  Recurrent UTI 1 7.1 
  Renal papillary necrosis 1 7.1 
  
Discussion
The 10 year prevalence of  0.056% observed in this study 
is comparable to the incidence of  this malignancy in the 
general population; which is 3.9 per 100,00012.The study 
by Davis et al2 found a higher incidence of  this malig-
nancy in individuals with sickle cell trait (HbAS), but not 
in homozygous HbSS people. However this study impli-
cated the sickling of  red cells in the pathogenesis of  this 
malignancy (as observed in the histology of  the diseased 
tissue) a hypothesis which if  correct, would render ho-
mozygous S individuals equally vulnerable. No study has 
demonstrated that kidney cancers are more prevalent in 
HbSS persons other than Baron et al 13 who found a 16.7 
fold excess in HbSS individuals, in a forty year retrospec-
tive study. However, the data was not expressed as preva-
lence rates; making it difficult to compare with the rate in 
the general population. Also, Barons study was targeted 
at African Americans in the United States of  America, 
diagnosed with RCC, and not on sickle cell patients, pri-
marily. The effect of  environmental exposure as well as 
occupational hazards leading to this predisposition has to 
be further evaluated.
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The incidence of  cancers of  the kidney and renal pelvis 
in African Americans has been estimated to be 23.3 in 
males and 12.1 in females per 100,000(equivalent to 0.23 
and 0.12 per 1000 respectively)14. This is higher than the 
estimated incidence of  5.6 per 100,000 observed in this 
study. Though this rate includes all malignancies of  the 
kidneys and renal pelvis in the normal population, it is 
known that RMC represents less than 1% of  the cancers 
of  the kidney11,15. Further more in the study by Davies et 
al, 62% of  the patients (34/55) with kidney cancer were 
found to have RMC. Therefore from the observed preva-
lence in this study, an estimated total prevalence of  16.8 
per 100,000 can be derived for cancers of  the kidney in 
HbSS individuals. This invariably suggests that HbSS pa-
tients do not have a higher tendency to develop RMC. 
The term “Seventh Nephropathy” in sickle cell therefore 
cannot be correctly ascribed to renal medullary carcino-
ma, as it has not been shown to have a higher incidence 
in people living with sickle cell disease.
The participants in this study were selected in a consecu-
tive and non-randomized manner, involving all physicians 
who obliged. This method of  sampling though not opti-
mal with regards to the bias, however provides some valu-
able information and also reveals the paucity of  docu-
mentation with regards to patients records in developing 
countries. The overall response rate amongst the centers 
invited to participate was approximately 65%. Either the 
result obtained therefore may be bloated or less than the 
real figures, however some deductions can be made from 
the results so far obtained.
The majority of  physicians included in this survey re-
ported that chronic kidney disease was the most common 
renal complication among their HbSS patients, followed 
by proteinuria and nephrotic syndrome. Previous studies 
had reported proteinuria (albuminuria) as the most com-
mon renal complication in SCD, with chronic renal failure 
(CRF) in 20% of  the patients16,17. This may be in the cir-
cumstance of  overt renal failure, though micro-albumin-
uria may be discovered in clinics where this is routinely 
screened, thus explaining its lower frequency. The finding 
from this study that chronic renal disease is the common-
est renal complication of  SCD is consistent with previous 
observations17. This further supports the routine screen-
ing for micro-albminuria in sickle cell patients as  a means 
of  preventing chronic kidney disease. HbSS patients have 
impaired immunity leading to recurrent urinary tract in-
fection, especially in children who may be asymptomatic. 
Papillary necrosis has been reported in 30-40% of  HbSS 
individuals, although this complication could be asymp-
tomatic in up to 62% of  those affected18. Only 7.1% of  
the physicians who conducted this study reported renal 
papillary necrosis as a common finding. However, it must 
be noted that a greater percentage of  HbSS patients actu-
ally have asymptomatic haematuria that can only be de-
tected by serial urinalysis or microscopy.
 
Conclusion
The 10 year prevalence of  renal medullary carcinoma in 
sickle cell disease patients was found to 0.056%. This is 
comparable to the incidence of  cancers of  the kidney in 
the overall population, and suggests that sickle cell disease 
patients do not have a higher tendency to develop renal 
medullary carcinoma. The term “Seventh Nephropathy 
of  Sickle cell” with regards to RMC, is inappropriate as 
HbSS does not confer a higher predisposition to the oc-
currence of  this malignancy.
Chronic kidney disease (CKD) was also found to be 
the commonest renal complication of  sickle cell disease 
found in people living with sickle cell disease.
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